

MBL International Corporation opens a new R&D laboratory

MBL International Corporation (MBLI), headquartered in Woburn, MA, USA, a wholly owned company of Medical & Biological Laboratories, Co., Ltd. in Japan in collaboration with SCIVAX USA, has announced opening a new R&D laboratory.

MBLI was established in a suburb of Boston in 1993 and has since that time been a leading life science company focused on providing high quality, innovative, solutions-based products for both life science research and clinical diagnostics in North America, South America, Europe and other countries. In the field of life science research, the company sells distinct antibodies and biological reagents in high demand by researchers. MBLI has recently started manufacturing and selling globally MHC Tetramer products which can detect antigen-specific T cells. In the epigenomic area, the company also plans to launch new antibodies which recognize characteristic modified nucleic acids. Regarding in vitro diagnostics, MBLI sells indirect immunofluorescence products for autoimmune and infectious diseases and ELISA products for autoimmune disease.

The laboratory will take a leading role in evaluating potential licensed products and technology in life science. It will also provide collaborative research with academia in developing novel research and diagnostic products, acquisition of application data for MBL products, and technical support for research reagents and in vitro diagnostic products to customers. MBLI will begin selling SCIVAX's 3D nanoculture plate products soon. The SCIVAX products will be an added asset to MBLI's research product portfolio.

The laboratory is a 3,000 square-foot facility equipped with immunological and molecular biological and R&D instrumentation. MBLI will evaluate novel product seeds, develop new MHC Tetramer products, and acquire new application data for the products in the areas of epigenetics, signal transduction and related products. Furthermore, the company plans to do research activities in collaboration with academia to explore biomarkers as future companion diagnostics.

In the future, MBLI will expand its laboratory capacity to develop new and novel products as one R&D hub among the MBL Group Companies.

CONTACT: E-Mail: kyamada@mblintl.com, Website: www.mblintl.com

Medical & Biological Laboratories, Co., Ltd. (MBL)

MBL was established as the first antibody manufacturing company in Japan in 1969. It is currently doing research, development, manufacturing and sales of in vitro diagnostic and research use reagents while expanding its business segments to molecular diagnostics and post-translational modification in addition to the immunological field. In the field of research reagents, the company is selling in global markets many different products such as more than 5,000 antibodies, contract manufactured antibodies, mRNA identification kits, oligonucleotides and artificial genes. In the field of in vitro diagnostics, MBL develops diagnostic reagents and molecular diagnostics for autoimmune, cancer and metabolic disorders. In the area of autoantibody diagnostics which includes many intractable diseases, MBL leads in providing a product portfolio which contributes to medical treatment. In the area of cytology, MBL sells automated histocytological preparation systems for diagnosis of cervical cancer, virus detection and typing reagents, and cell collection tools.

For more information, please visit <http://www.mbl.co.jp>.

MBL International Corporation (MBLI)

MBLI, headquartered in Woburn, MA, was established in 1993 as a wholly owned subsidiary of Medical & Biological Laboratories, Co., Ltd. The company has provided research reagents in life science and clinical diagnostic products manufactured by MBL to the USA and Europe. Through the acquisition of Bion Enterprises, Ltd. in 2008, MBLI expanded its diagnostic portfolio to include immunofluorescence assay products, further strengthening its autoimmune and infectious disease product offering. MBLI licensed the entire portfolio of MHC tetramer products from Beckman Coulter in 2013, and started selling the products in the USA and Europe. MBLI's sales territories include North America, Europe, Central America, South America, and the Middle East through India.

For more information, please visit <http://www.mblintl.com/>.

SCIVAX USA

SCIVAX USA, INC. headquartered in Woburn, MA, USA, is a leading 3D cell culture technology company having the original Micro-Patterned Surface technology based 3D cell culture ware "NanoCulture Plate (NCP)". NCP enables easy culturing of in vivo like 3D multi-cellular spheroids, using the same technique as in monolayer cell culture. Its "Minimal-Attachment" concept gives an in vivo like anchorage-independent growth environment to the spheroids formed. Its capability is highly valued by both pharmaceutical companies and academic institutes, with growing users in Japan, the USA and Europe. SCIVAX USA is a 100% owned subsidiary of SCIVAX Life Science, Inc., which is a 100% owned subsidiary of JSR Corporation, a leading Japanese synthetic rubber and plastic manufacturing company who owns diversified business fields including semiconductor and life sciences.

For more information, visit <http://www.scivax.com/usa/>